Background: Identifying predictors of conversion to Alzheimer’s disease (AD) is critically important for AD prevention and targeted treatment.
Objective: To compare various clinical and biomarker trajectories for tracking progression and predicting conversion from amnestic mild cognitive impairment to probable AD.
Methods: Participants were from the ADNI-1 study. We assessed the ability of 33 longitudinal biomarkers to predict time to AD conversion, accounting for demographic and genetic factors. We used joint modelling of longitudinal and survival data to examine the association between changes of measures and disease progression. We also employed time-dependent receiver operating characteristic method to assess the discriminating capability of the measures.
Results: 23 of 33 longitudinal clinical and imaging measures are significant predictors of AD conversion beyond demographic and genetic factors. The strong phenotypic and biological predictors are in the cognitive domain (ADAS-Cog; RAVLT), functional domain (FAQ), and neuroimaging domain (middle temporal gyrus and hippocampal volume). The strongest predictor is ADAS-Cog 13 with an increase of one SD in ADAS-Cog 13 increased the risk of AD conversion by 2.92 times.
Conclusion: Prediction of AD conversion can be improved by incorporating longitudinal change information, in addition to baseline characteristics. Cognitive measures are consistently significant and generally stronger predictors than imaging measures.
ManlyJJ, TangM-X, SchupfN, SternY, VonsattelJ-PG, MayeuxR (2008) Frequency and course of mild cognitive impairment in a multiethnic community. Ann Neurol63, 494–506.
3.
JackCR, PetersenRC, XuYC, O’BrienPC, SmithGE, IvnikRJ, BoeveBF, WaringSC, TangalosEG, KokmenE (1999) Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology52, 1397–1397.
4.
RisacherSL, SaykinAJ, WestJD, ShenL, FirpiHA, McDonaldBC (2009) Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res6, 347–361.
5.
DavatzikosC, XuF, AnY, FanY, ResnickSM (2009) Longitudinal progression of Alzheimer’s-like patterns of atrophy in normal older adults: The SPARE-AD index. Brain132, 2026–2035.
6.
MosconiL, BertiV, GlodzikL, PupiA, De SantiS, de LeonMJ (2010) Pre-clinical detection of Alzheimer’s disease usingFDG-PET, with or without amyloid imaging. J AlzheimersDis20, 843–854.
7.
ChapmanRM, MapstoneM, McCraryJW, GardnerMN, PorsteinssonA, SandovalTC, GuillilyMD, DeGrushE, ReillyLA (2011) Predicting conversion from mild cognitive impairment to Alzheimer’s disease using neuropsychological tests and multivariate methods. J Clin Exp Neuropsychol33, 187–199.
8.
DickersonBC, SperlingRA, HymanBT, AlbertMS, BlackerD (2007) Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment. Arch Gen Psychiatry64, 1443–1450.
9.
FleisherAS, SowellBB, TaylorC, GamstAC, PetersenRC, ThalLJ, Alzheimer’s Disease Cooperative Study (2007) Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology68, 1588–1595.
10.
FjellAM, WalhovdKB, Fennema-NotestineC, McEvoyLK, HaglerDJ, HollandD, BrewerJB, DaleAM; Alzheimer’s Disease Neuroimaging Initiative (2010) CSF biomarkers in prediction of cerebral andclinical change in mild cognitive impairment and Alzheimer’sdisease. J Neurosci30, 2088–2101.
ZhangD, ShenD, Alzheimer’sDisease Neuroimaging Initiative (2012) Predicting future clinical changes of MCI patients usinglongitudinal and multimodal biomarkers. PLoS One7, e33182.
16.
VellasB, CarrilloMC, SampaioC, BrashearHR, SiemersE, HampelH, SchneiderLS, WeinerM, DoodyR, KhachaturianZ, CedarbaumJ, GrundmanM, BroichK, GiacobiniE, DuboisB, SperlingR, WilcockGK, FoxN, ScheltensP, TouchonJ, HendrixS, AndrieuS, AisenP, EU/US/CTAD Task Force Members (2013) Designing drug trials for Alzheimer’s disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force. Alzheimers Dement9, 438–444.
LenzRA, PritchettYL, BerrySM, LlanoDA, HanS, BerryDA, SadowskyCH, Abi-SaabWM, SaltarelliMD (2015) Adaptive, dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate Alzheimer disease. Alzheimer Dis Assoc Disord29, 192–199.
19.
FaucettCL, ThomasDC (1996) Simultaneously modelling censored survival data and repeatedly measured covariates: A Gibbs sampling approach. Stat Med15, 1663–1685.
20.
WulfsohnMS, TsiatisAA (1997) A joint model for survival and longitudinal data measured with error. Biometrics53, 330–339.
21.
LandauSM, HarveyD, MadisonCM, KoeppeRA, ReimanEM, FosterNL, WeinerMW, JagustWJ; Alzheimer’s Disease Neuroimaging Initiative (2011) Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging32, 1207–1218.
JackCR, KnopmanDS, JagustWJ, ShawLM, AisenPS, WeinerMW, PetersenRC, TrojanowskiJQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’spathological cascade. Lancet Neurol9, 119.
34.
LiS, OkonkwoO, AlbertM, WangM-C (2013) Variation in variables that predict progression from MCI to AD dementia over duration of follow-up. Am J Alzheimers Dis (Columbia)2, 12–28.
35.
CuiY, LiuB, LuoS, ZhenX, FanM, LiuT, ZhuW, ParkM, JiangT, JinJS, Alzheimer’s Disease Neuroimaging Initiative (2011) Identification of conversion from mild cognitive impairment toAlzheimer’s disease using multivariate predictors. PLoS One6, e21896.
36.
GomarJJ (2011) Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer’s Disease Neuroimaging Initiative. Arch Gen Psychiatry68, 961.
37.
EwersM, WalshC, TrojanowskiJQ, ShawLM, PetersenRC, JackCR, FeldmanHH, BokdeALW, AlexanderGE, ScheltensP, VellasB, DuboisB, WeinerM, HampelH; North American Alzheimer’s Disease Neuroimaging Initiative (ADNI) (2012) Prediction of conversion from mild cognitive impairment to Alzheimer’s disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging33, 1203–1214.e2.
38.
HeB, LuoS (2016) Joint modeling of multivariate longitudinal measurements and survival data with applications to Parkinson’s disease. Stat Methods Med Res25, 1346–1358.
39.
WangJ, LuoS, LiL (2016) Dynamic prediction for multiple repeated measures and event time data: An application to Parkinson’s disease, arXiv:1603.06476.
